Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress
Vito A. G. Ricigliano(Inserm), Serena Borrelli(Université Libre de Bruxelles), Hans-Peter Hartung(The University of Sydney), Sara Samadzadeh(University of Southern Denmark), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Silvia Marenna(Vita-Salute San Raffaele University), Edgar Carnero Contentti(Hospital Alemán), Christos Bakirtzis(Aristotle University of Thessaloniki), Gıancarlo Comı(Vita-Salute San Raffaele University), Sanja Gluščević(University of Montenegro), Valentina Camera(University of Oxford), Bruno Stankoff(Pitié-Salpêtrière Hospital), Natalia Szejko(University of Calgary)
Cited by 11
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Multiple Sclerosis Severity Score
|Neurology|2005|957
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706